TC BioPharm (Holdings) plc Warrants (TCBPW)TCBPW

TC BioPharm (Holdings) plc Warrants: A Comprehensive Overview

Company Profile:

History and Background:

TC BioPharm (Holdings) plc Warrants (TCBPW) is a company that provides the right to purchase shares of TC BioPharm (Holdings) plc (TCBP), a clinical-stage biotechnology company focused on the development of cancer therapies. TCBP was incorporated in the Cayman Islands in 2017. The warrants were issued in conjunction with the company's initial public offering (IPO) in October 2020.

Core Business Areas:

TCBP's core business areas are:

• Development of targeted therapies for solid tumors: This includes TCBP-001, a small molecule inhibitor of the protein lysine methyltransferase (PKMT) enzyme, which is currently in Phase I clinical trials for the treatment of advanced hepatocellular carcinoma (HCC).
• Development of cancer vaccines: TCBP is developing a personalized neoantigen vaccine platform, TCBP-002, for the treatment of various cancers. This platform is still in the preclinical stage.
• Immuno-oncology therapies: TCBP is also developing additional immuno-oncology therapies, including TCBP-003, which is a next-generation chimeric antigen receptor (CAR) T-cell therapy, also in the preclinical stage.

Leadership Team and Corporate Structure:

• Yu Xue, Ph.D.: Chairman and Chief Executive Officer. Dr. Xue has over 20 years of experience in the pharmaceutical industry, including leadership roles at Gilead Sciences and Bristol-Myers Squibb.
• Wenbin Jiang, Ph.D.: Chief Medical Officer. Dr. Jiang has over 15 years of experience in clinical development, including leadership roles at AstraZeneca and Pfizer.
• Honglin Luo, Ph.D.: Chief Scientific Officer. Dr. Luo has over 20 years of experience in drug discovery and development, including leadership roles at Merck and Pfizer.

Top Products and Market Share:

Top Products and Offerings:

• TCBP-001: A PKMT inhibitor currently in Phase I clinical trials for the treatment of HCC. HCC is the most common type of liver cancer and has a poor prognosis.
• TCBP-002: A personalized neoantigen vaccine platform for the treatment of various cancers. This platform is still in the preclinical stage.
• TCBP-003: A next-generation CAR T-cell therapy in the preclinical stage.

Market Share:

TCBP is a clinical-stage company with no marketed products. Therefore, it has no current market share. However, the global market for cancer therapies is estimated to be worth over US$150 billion and is expected to grow significantly in the coming years.

Product Performance and Market Reception:

It is still too early to assess the product performance and market reception of TCBP's products as they are still in the preclinical or early clinical stages of development.

Total Addressable Market:

The total addressable market for TCBP's cancer therapies is vast. The global market for cancer therapies is estimated to be worth over US$150 billion and is expected to grow to over US$250 billion by 2027.

Financial Performance:

Recent Financial Statements:

TCBP is a clinical-stage company with no marketed products. As of June 30, 2023, the company had a cash balance of approximately US$38.5 million. During the six months ended June 30, 2023, the company reported a net loss of approximately US$14.5 million.

Year-over-Year Financial Performance Comparison:

TCBP is a relatively new company with limited historical financial data. However, the company's net loss decreased from approximately US$16.3 million in the six months ended June 30, 2022, to approximately US$14.5 million in the six months ended June 30, 2023.

Cash Flow and Balance Sheet Health:

As of June 30, 2023, TCBP had a cash balance of approximately US$38.5 million. The company's cash burn rate is approximately US$9.5 million per quarter. The company's balance sheet is relatively healthy, with total assets of approximately US$4